Literature DB >> 3929660

Determination of in vitro susceptibility of mycobacteria to ansamycin.

L B Heifets, M D Iseman.   

Abstract

The in vitro susceptibility of different mycobacterial species to ansamycin (LM427) in concentrations of 2.0, 1.0, 0.5, and 0.2 micrograms/ml was determined by the agar dilution method. For those strains of M. tuberculosis and M. avium complex tested, susceptibility to ansamycin was compared with susceptibility to rifampin. All M. tuberculosis strains susceptible to rifampin were susceptible to ansamycin; the strains that were highly resistant to rifampin also were resistant to ansamycin. The majority of M. avium complex strains were "naturally" resistant to rifampin (1.0 micrograms/ml and higher), but only approximately 13% of them were resistant to ansamycin in a concentration of 1.0 microgram/ml. The cross-resistance in M. avium strains was made apparent only by comparing patterns of resistance to low concentrations of ansamycin (0.5 microgram/ml) with patterns of resistance to higher concentrations of rifampin (5.0 and 10.0 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929660     DOI: 10.1164/arrd.1985.132.3.710

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  15 in total

1.  Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Authors:  U Hjelm; J Kaustová; M Kubín; S E Hoffner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 4.  Antimycobacterial susceptibility testing: present practices and future trends.

Authors:  C B Inderlied
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

5.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.

Authors:  L K Yuen; D Leslie; P J Coloe
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

8.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

9.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 10.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.